DouYu Intl Hldgsの空売り状況は、投資家がDouYu Intl Hldgsの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

DouYu Intl Hldgs (NASDAQ:DOYU) 株価情報, 空売り情報

DouYu Intl Hldgs

DouYu International Holdings Ltd is a game-centric live streaming platform in China and a pioneer in the eSports value chain. The company operates its platform on both PC and mobile apps, through which users can enjoy immersive and interactive games and entertainment live streaming. It generates revenues through live streaming and advertisement.

DouYu International Holdings Limited - American Depositary Shares

DouYu International Holdings Ltd

Citigroup analyst Steven Enders maintains Open Text (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OTEX#NASDAQ">OTEX</a>) with a Neutral and lowers the price target from $33 to $30.

News

Price Target

Analyst Ratings

OTEX

Citigroup Maintains Neutral on Open Text, Lowers Price Target to $30

Financial giants have made a conspicuous bearish move on Duolingo. Our analysis of options history for Duolingo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DUOL#NASDAQ">DUOL</a>) revealed 8 unusual trades.
Delving into the details, we found 25% of traders were bullish, while 50% showed bearish tendencies. Out of all the trades we spotted, 2 were puts, with a value of $108,187, and 6 were calls, valued at $405,960.
<h3>Expected Price Movements</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $250.0 to $390.0 for Duolingo during the past quarter. 
<h3>Volume &amp; Open Interest Development</h3>
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Duolingo's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Duolingo's significant trades, within a strike price range of $250.0 to $390.0, over the past month.
<h3>Duolingo Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1737054071_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>DUOL</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>05/16/25</td>
<td>$112.8</td>
<td>$111.3</td>
<td>$111.7</td>
<td>$250.00</td>
<td>$122.8K</td>
<td align="right">7</td>
<td align="right">11</td>
</tr>
<tr>
<td>DUOL</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>05/16/25</td>
<td>$71.9</td>
<td>$68.9</td>
<td>$70.5</td>
<td>$300.00</td>
<td>$91.6K</td>
<td align="right">26</td>
<td align="right">13</td>
</tr>
<tr>
<td>DUOL</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$18.0</td>
<td>$17.4</td>
<td>$18.0</td>
<td>$350.00</td>
<td>$82.6K</td>
<td align="right">13</td>
<td align="right">49</td>
</tr>
<tr>
<td>DUOL</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$9.5</td>
<td>$9.0</td>
<td>$9.0</td>
<td>$390.00</td>
<td>$73.7K</td>
<td align="right">32</td>
<td align="right">89</td>
</tr>
<tr>
<td>DUOL</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$93.5</td>
<td>$92.4</td>
<td>$92.4</td>
<td>$330.00</td>
<td>$46.2K</td>
<td align="right">9</td>
<td align="right">6</td>
</tr>
</tbody>
</table>

<h3>About Duolingo</h3>
Duolingo Inc is a technology company that develops mobile learning platform to learn languages and is the top-grossing app in the Education category on both Google Play and the Apple App Store. Its products are powered by sophisticated data analytics and artificial intelligence and delivered with class art, animation, and design to make it easier for learners to stay motivated master new material, and achieve their learning goals. Its solutions include The Duolingo Language Learning App, Super Duolingo, Duolingo English Test: AI-Driven Language Assessment, Duolingo For Schools, Duolingo ABC, and Duolingo Math. It has three predominant sources of revenue; time-based subscriptions, in-app advertising placement by third parties, and the Duolingo English Test.
Having examined the options trading patterns of Duolingo, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Present Market Standing of Duolingo</h3>
<ul>
<li>With a volume of 645,532, the price of DUOL is up 7.98% at $345.5. </li>
<li>RSI indicators hint that the underlying stock may be approaching overbought.</li>
<li>Next earnings are expected to be released in 41 days.</li>
</ul>
<h3>Expert Opinions on Duolingo</h3>
Over the past month, 1 industry analysts have shared their insights on this stock, proposing an average target price of $385.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Needham has decided to maintain their Buy rating on Duolingo, which currently sits at a price target of $385. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Duolingo with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

Options

Markets

DUOL

Smart Money Is Betting Big In DUOL Options

Investors with a lot of money to spend have taken a bearish stance on Astera Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALAB#NASDAQ">ALAB</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with ALAB, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 11 uncommon options trades for Astera Labs.
This isn't normal.
The overall sentiment of these big-money traders is split between 18% bullish and 63%, bearish.
Out of all of the special options we uncovered, 6 are puts, for a total amount of $733,028, and 5 are calls, for a total amount of $338,840.
<h3>Projected Price Targets</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $100.0 to $150.0 for Astera Labs during the past quarter. 
<h3>Volume &amp; Open Interest Development</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for Astera Labs's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Astera Labs's whale activity within a strike price range from $100.0 to $150.0 in the last 30 days. 
<h3>Astera Labs 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1737054065_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>ALAB</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>07/18/25</td>
<td>$23.9</td>
<td>$23.2</td>
<td>$23.9</td>
<td>$125.00</td>
<td>$239.0K</td>
<td>29</td>
<td align="right">100</td>
</tr>
<tr>
<td>ALAB</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>07/18/25</td>
<td>$16.3</td>
<td>$15.7</td>
<td>$16.3</td>
<td>$110.00</td>
<td>$163.0K</td>
<td>188</td>
<td align="right">0</td>
</tr>
<tr>
<td>ALAB</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>07/18/25</td>
<td>$16.3</td>
<td>$15.6</td>
<td>$16.3</td>
<td>$110.00</td>
<td>$163.0K</td>
<td>188</td>
<td align="right">200</td>
</tr>
<tr>
<td>ALAB</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$12.7</td>
<td>$11.4</td>
<td>$11.52</td>
<td>$130.00</td>
<td>$115.7K</td>
<td>1.8K</td>
<td align="right">131</td>
</tr>
<tr>
<td>ALAB</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$11.6</td>
<td>$10.8</td>
<td>$11.12</td>
<td>$140.00</td>
<td>$109.5K</td>
<td>527</td>
<td align="right">100</td>
</tr>
</tbody>
</table>

<h3>About Astera Labs</h3>
Astera Labs Inc is a company that offers an Intelligent Connectivity Platform, comprised of Semiconductor-based, high-speed mixed-signal connectivity products that integrate a matrix of microcontrollers and sensors. COSMOS, their software suite which is embedded in its connectivity products and integrated into their customers' systems. The Company delivers critical connectivity performance, enables flexibility and customization, and supports observability and predictive analytics. This approach addresses the data, network, and memory bottlenecks, scalability, and other infrastructure requirements of hyperscalers and system original equipment manufacturers.
Following our analysis of the options activities associated with Astera Labs, we pivot to a closer look at the company's own performance.
<h3>Where Is Astera Labs Standing Right Now?</h3>
<ul>
<li>Currently trading with a volume of 2,217,628, the ALAB's price is down by -5.91%, now at $123.98. </li>
<li>RSI readings suggest the stock is currently is currently neutral between overbought and oversold.</li>
<li>Anticipated earnings release is in 25 days.</li>
</ul>
<h3>Expert Opinions on Astera Labs</h3>
3 market experts have recently issued ratings for this stock, with a consensus target price of $137.33333333333334.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; In a cautious move, an analyst from Northland Capital Markets downgraded its rating to Market Perform, setting a price target of $120. 
&#x2A; An analyst from Morgan Stanley persists with their Overweight rating on Astera Labs, maintaining a target price of $142. 
&#x2A; An analyst from Stifel has decided to maintain their Buy rating on Astera Labs, which currently sits at a price target of $150. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Astera Labs with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

ALAB

Decoding Astera Labs's Options Activity: What's the Big Picture?

Throughout the last three months, 11 analysts have evaluated DexCom (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>), offering a diverse set of opinions from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">7</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">5</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $95.91, a high estimate of $115.00, and a low estimate of $85.00. This upward trend is evident, with the current average reflecting a 2.73% increase from the previous average price target of $93.36.
<img src="https://www.benzinga.com/files/images/story/2025/1737054064_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
The perception of DexCom by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jeff Johnson</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$104.00</td>
<td>$86.00</td>
</tr>
<tr>
<td>Joanne Wuensch</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$91.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Larry Biegelsen</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$94.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>William Plovanic</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$99.00</td>
<td>$89.00</td>
</tr>
<tr>
<td>Lee Hambright</td>
<td>Bernstein</td>
<td>Raises</td>
<td>Outperform</td>
<td>$86.00</td>
<td>$82.00</td>
</tr>
<tr>
<td>Jayson Bedford</td>
<td>Raymond James</td>
<td>Lowers</td>
<td>Strong Buy</td>
<td>$99.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$115.00</td>
<td>$120.00</td>
</tr>
<tr>
<td>Steven Lichtman</td>
<td>Oppenheimer</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$105.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Robbie Marcus</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$85.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Mike Kratky</td>
<td>Leerink Partners</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$87.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Larry Biegelsen</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$90.00</td>
<td>$80.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to DexCom. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of DexCom compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of DexCom's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of DexCom's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/DXCM/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on DexCom analyst ratings.</a>
<h2>All You Need to Know About DexCom</h2>
Dexcom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery.
<h3>Financial Insights: DexCom</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Over the 3 months period, DexCom showcased positive performance, achieving a revenue growth rate of 1.97% as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: DexCom's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of 13.54%, the company may face hurdles in effective cost management.
Return on Equity (ROE): DexCom's ROE excels beyond industry benchmarks, reaching 6.1%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of 2.05%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: With a high debt-to-equity ratio of 1.31, DexCom faces challenges in effectively managing its debt levels, indicating potential financial strain.
<h2>The Basics of Analyst Ratings</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

DXCM

Expert Outlook: DexCom Through The Eyes Of 11 Analysts

Investors with a lot of money to spend have taken a bullish stance on American Express (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AXP#NYSE">AXP</a>).
And retail traders should know.
We noticed this today when the positions showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with AXP, it often means somebody knows something is about to happen.
Today, Benzinga's options scanner spotted 16 options trades for American Express.
This isn't normal.
The overall sentiment of these big-money traders is split between 43% bullish and 37%, bearish.
Out of all of the options we uncovered, there was 1 put, for a total amount of $98,600, and 15, calls, for a total amount of $1,345,104.
<h3>What's The Price Target?</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $160.0 to $320.0 for American Express over the last 3 months. 
<h3>Volume &amp; Open Interest Trends</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for American Express's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of American Express's whale activity within a strike price range from $160.0 to $320.0 in the last 30 days. 
<h3>American Express 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1737054060_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>AXP</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$37.8</td>
<td>$36.95</td>
<td>$37.7</td>
<td>$290.00</td>
<td>$754.0K</td>
<td align="right">906</td>
<td align="right">10</td>
</tr>
<tr>
<td>AXP</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$154.0</td>
<td>$152.4</td>
<td>$154.0</td>
<td>$160.00</td>
<td>$154.0K</td>
<td align="right">104</td>
<td align="right">10</td>
</tr>
<tr>
<td>AXP</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$17.0</td>
<td>$16.55</td>
<td>$17.0</td>
<td>$320.00</td>
<td>$98.6K</td>
<td align="right">100</td>
<td align="right">61</td>
</tr>
<tr>
<td>AXP</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$16.3</td>
<td>$15.7</td>
<td>$16.3</td>
<td>$310.00</td>
<td>$55.4K</td>
<td align="right">943</td>
<td align="right">40</td>
</tr>
<tr>
<td>AXP</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/31/25</td>
<td>$5.1</td>
<td>$4.65</td>
<td>$5.1</td>
<td>$320.00</td>
<td>$50.4K</td>
<td align="right">139</td>
<td align="right">116</td>
</tr>
</tbody>
</table>

<h3>About American Express</h3>
American Express is a global financial institution, operating in about 130 countries, that provides consumers and businesses charge and credit card payment products. The company also operates a highly profitable merchant payment network. Since 2018, it has operated in three segments: global consumer services, global commercial services, and global merchant and network services. In addition to payment products, the company's commercial business offers expense management tools, consulting services, and business loans.
Having examined the options trading patterns of American Express, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Where Is American Express Standing Right Now?</h3>
<ul>
<li>With a volume of 1,175,128, the price of AXP is down -0.31% at $311.34. </li>
<li>RSI indicators hint that the underlying stock may be approaching overbought.</li>
<li>Next earnings are expected to be released in 8 days.</li>
</ul>
<h3>Professional Analyst Ratings for American Express</h3>
Over the past month, 5 industry analysts have shared their insights on this stock, proposing an average target price of $321.4.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from UBS persists with their Neutral rating on American Express, maintaining a target price of $320. 
&#x2A; Consistent in their evaluation, an analyst from Compass Point keeps a Neutral rating on American Express with a target price of $325. 
&#x2A; An analyst from Morgan Stanley persists with their Equal-Weight rating on American Express, maintaining a target price of $305. 
&#x2A; An analyst from Truist Securities downgraded its action to Buy with a price target of $350. 
&#x2A; Maintaining their stance, an analyst from JP Morgan continues to hold a Neutral rating for American Express, targeting a price of $307. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for American Express, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

American Express's Options: A Look at What the Big Money is Thinking

During the last three months, 10 analysts shared their evaluations of Procter &amp; Gamble (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PG#NYSE">PG</a>), revealing diverse outlooks from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">5</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $182.3, a high estimate of $209.00, and a low estimate of $160.00. This current average has increased by 2.99% from the previous average price target of $177.00. 
<img src="https://www.benzinga.com/files/images/story/2025/1737054054_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
The analysis of recent analyst actions sheds light on the perception of Procter &amp; Gamble by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Andrea Teixeira</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$181.00</td>
<td>$186.00</td>
</tr>
<tr>
<td>Chris Carey</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$176.00</td>
<td>$190.00</td>
</tr>
<tr>
<td>Linda Bolton Weiser</td>
<td>DA Davidson</td>
<td>Maintains</td>
<td>Buy</td>
<td>$209.00</td>
<td>$209.00</td>
</tr>
<tr>
<td>Linda Bolton Weiser</td>
<td>DA Davidson</td>
<td>Raises</td>
<td>Buy</td>
<td>$209.00</td>
<td>$160.00</td>
</tr>
<tr>
<td>Chris Carey</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$190.00</td>
<td>$188.00</td>
</tr>
<tr>
<td>Linda Bolton Weiser</td>
<td>DA Davidson</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$160.00</td>
<td>$160.00</td>
</tr>
<tr>
<td>Dara Mohsenian</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$191.00</td>
<td>$174.00</td>
</tr>
<tr>
<td>Robert Ottenstein</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$183.00</td>
<td>$180.00</td>
</tr>
<tr>
<td>Nik Modi</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Sector Perform</td>
<td>$164.00</td>
<td>$164.00</td>
</tr>
<tr>
<td>Linda Bolton Weiser</td>
<td>DA Davidson</td>
<td>Raises</td>
<td>Neutral</td>
<td>$160.00</td>
<td>$159.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Procter &amp; Gamble. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Procter &amp; Gamble compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Procter &amp; Gamble's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Procter &amp; Gamble's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/PG/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Procter &amp; Gamble analyst ratings.</a>
<h2>All You Need to Know About Procter &amp; Gamble</h2>
Since its founding in 1837, Procter &amp; Gamble has become one of the world's largest consumer product manufacturers, generating more than $80 billion in annual sales. It operates with a lineup of leading brands, including more than 20 that generate north of $1 billion each in annual global sales, such as Tide laundry detergent, Charmin toilet paper, Pantene shampoo, and Pampers diapers. Sales outside its home turf represent more than half of the firm's consolidated total.
<h3>Key Indicators: Procter &amp; Gamble's Financial Health</h3>
Market Capitalization: Positioned above industry average, the company's market capitalization underscores its superiority in size, indicative of a strong market presence.
Revenue Challenges: Procter &amp; Gamble's revenue growth over 3 months faced difficulties. As of 30 September, 2024, the company experienced a decline of approximately -0.61%. This indicates a decrease in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Consumer Staples sector.
Net Margin: Procter &amp; Gamble's net margin excels beyond industry benchmarks, reaching 17.88%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Procter &amp; Gamble's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of 7.73%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 3.12%, the company showcases effective utilization of assets.
Debt Management: Procter &amp; Gamble's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.71.
<h2>What Are Analyst Ratings?</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

10 Analysts Have This To Say About Procter & Gamble

In the latest quarter, 5 analysts provided ratings for Sally Beauty Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SBH#NYSE">SBH</a>), showcasing a mix of bullish and bearish perspectives.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Sally Beauty Holdings, revealing an average target of $13.8, a high estimate of $16.00, and a low estimate of $12.00. This current average reflects an increase of 17.45% from the previous average price target of $11.75. 
<img src="https://www.benzinga.com/files/images/story/2025/1737054047_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
The perception of Sally Beauty Holdings by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Susan Anderson</td>
<td>Canaccord Genuity</td>
<td>Announces</td>
<td>Buy</td>
<td>$14.00</td>
<td>-</td>
</tr>
<tr>
<td>Oliver Chen</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Buy</td>
<td>$16.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Oliver Chen</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Hold</td>
<td>$14.00</td>
<td>$13.00</td>
</tr>
<tr>
<td>Linda Bolton Weiser</td>
<td>DA Davidson</td>
<td>Raises</td>
<td>Neutral</td>
<td>$13.00</td>
<td>$12.00</td>
</tr>
<tr>
<td>Simeon Gutman</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Underweight</td>
<td>$12.00</td>
<td>$8.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Sally Beauty Holdings. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Sally Beauty Holdings compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Sally Beauty Holdings's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Capture valuable insights into Sally Beauty Holdings's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/SBH/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Sally Beauty Holdings analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>All You Need to Know About Sally Beauty Holdings</h2>
Sally Beauty Holdings Inc is a professional beauty-products retailer based in the United States. Sally Beauty operates throughout the United States, Puerto Rico, the United Kingdom, Belgium, Canada, Chile, Mexico, Peru, France, Ireland, Spain, Germany, and the Netherlands. The company operates through two business segments: Sally Beauty Supply and Beauty Systems Group. Product offerings include hair color and care, hair dryers and hair-styling appliances, nail care, skin care, and others.
<h3>A Deep Dive into Sally Beauty Holdings's Financials</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Revenue Growth: Over the 3 months period, Sally Beauty Holdings showcased positive performance, achieving a revenue growth rate of 1.48% as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Consumer Discretionary sector.
Net Margin: Sally Beauty Holdings's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 5.14% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Sally Beauty Holdings's ROE excels beyond industry benchmarks, reaching 7.97%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 1.74%, the company showcases effective utilization of assets.
Debt Management: Sally Beauty Holdings's debt-to-equity ratio surpasses industry norms, standing at 2.54. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
<h2>What Are Analyst Ratings?</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

The Analyst Verdict: Sally Beauty Holdings In The Eyes Of 5 Experts

WIIM

POAI

Predictive Oncology shares are trading higher after the company announced the European launch of ChemoFx, its drug response assay. The drug is targeting 250,000 annual gynecologic cancer diagnoses with plans for expansion into the U.S. as well.

Remitly Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RELY#NASDAQ">RELY</a>) underwent analysis by 6 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Remitly Global and provided 12-month price targets. The average target is $21.33, accompanied by a high estimate of $25.00 and a low estimate of $18.00. This upward trend is apparent, with the current average reflecting a 17.39% increase from the previous average price target of $18.17.
<img src="https://www.benzinga.com/files/images/story/2025/1737054038_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
The perception of Remitly Global by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Andrew Bauch</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$21.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>Ramsey El-Assal</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$23.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Ramsey El-Assal</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$20.00</td>
<td>$16.00</td>
</tr>
<tr>
<td>Josh Beck</td>
<td>Keybanc</td>
<td>Raises</td>
<td>Overweight</td>
<td>$21.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>David Scharf</td>
<td>JMP Securities</td>
<td>Raises</td>
<td>Market Outperform</td>
<td>$25.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Andrew Bauch</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$18.00</td>
<td>$13.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Remitly Global. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Remitly Global compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Remitly Global's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
For valuable insights into Remitly Global's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/RELY/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Remitly Global analyst ratings.</a>
<h2>About Remitly Global</h2>
Remitly Global Inc provides integrated financial services to immigrants, including helping customers send money internationally in a quick, reliable, and more cost-effective manner by leveraging digital channels. It supports cross-border transmissions across the globe. The company's revenue is generated on transaction fees charged to customers and foreign exchange spreads between the foreign exchange rate offered to customers and the foreign exchange rate on the company's currency purchases.
<h3>Unraveling the Financial Story of Remitly Global</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Positive Revenue Trend: Examining Remitly Global's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 39.27% as of 30 September, 2024, showcasing a substantial increase in top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Financials sector.
Net Margin: Remitly Global's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of 0.57%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): Remitly Global's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of 0.32%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of 0.2%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: With a below-average debt-to-equity ratio of 0.02, Remitly Global adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>How Are Analyst Ratings Determined?</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

RELY

Demystifying Remitly Global: Insights From 6 Analyst Reviews

Providing a diverse range of perspectives from bullish to bearish, 12 analysts have published ratings on Synovus Finl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNV#NYSE">SNV</a>) in the last three months.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">4</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $61.12, a high estimate of $76.00, and a low estimate of $54.00. This upward trend is apparent, with the current average reflecting a 10.93% increase from the previous average price target of $55.10.
<img src="https://www.benzinga.com/files/images/story/2025/1737054028_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
The analysis of recent analyst actions sheds light on the perception of Synovus Finl by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Russell Gunther</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Equal-Weight</td>
<td>$58.00</td>
<td>$58.00</td>
</tr>
<tr>
<td>Anthony Elian</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$60.50</td>
<td>$63.00</td>
</tr>
<tr>
<td>Nicholas Holowko</td>
<td>UBS</td>
<td>Announces</td>
<td>Buy</td>
<td>$76.00</td>
<td>-</td>
</tr>
<tr>
<td>Jon Arfstrom</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$64.00</td>
<td>$64.00</td>
</tr>
<tr>
<td>Brad Milsaps</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$64.00</td>
<td>$56.00</td>
</tr>
<tr>
<td>Bernard von-Gizycki</td>
<td>Deutsche Bank</td>
<td>Announces</td>
<td>Buy</td>
<td>$64.00</td>
<td>-</td>
</tr>
<tr>
<td>Timur Braziler</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$55.00</td>
<td>$51.00</td>
</tr>
<tr>
<td>Ryan Nash</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Neutral</td>
<td>$62.00</td>
<td>$52.00</td>
</tr>
<tr>
<td>Jared Shaw</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$64.00</td>
<td>$56.00</td>
</tr>
<tr>
<td>John Pancari</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>In-Line</td>
<td>$54.00</td>
<td>$48.00</td>
</tr>
<tr>
<td>Manan Gosalia</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$55.00</td>
<td>$51.00</td>
</tr>
<tr>
<td>Brandon King</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$57.00</td>
<td>$52.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Synovus Finl. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Synovus Finl compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Synovus Finl's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Synovus Finl's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/SNV/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Synovus Finl analyst ratings.</a>
<h2>Get to Know Synovus Finl Better</h2>
Synovus Financial Corp provides commercial and consumer banking in addition to a full suite of specialized products &amp; services such as private banking, treasury management, wealth management, mortgage services, premium finance, asset-based lending, structured lending, capital markets, &amp; international banking to clients through the wholly-owned subsidiary bank, Synovus Bank, and other offices in Alabama, Florida, Georgia, South Carolina, and Tennessee. It has four segments Wholesale Banking, Community Banking, Consumer Banking, and Financial Management Services, out of which the majority is from the Wholesale banking segment.
<h3>Synovus Finl: A Financial Overview</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Positive Revenue Trend: Examining Synovus Finl's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 7.65% as of 30 September, 2024, showcasing a substantial increase in top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Financials sector.
Net Margin: Synovus Finl's net margin is impressive, surpassing industry averages. With a net margin of 30.51%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Synovus Finl's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 3.63%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Synovus Finl's ROA excels beyond industry benchmarks, reaching 0.28%. This signifies efficient management of assets and strong financial health.
Debt Management: Synovus Finl's debt-to-equity ratio is below the industry average. With a ratio of 0.42, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

12 Analysts Assess Synovus Finl: What You Need To Know

Zeta Global Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZETA#NYSE">ZETA</a>) has been analyzed by 22 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">11</td>
<td align="right">6</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">8</td>
<td align="right">4</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $37.73, a high estimate of $45.00, and a low estimate of $23.00. Witnessing a positive shift, the current average has risen by 3.51% from the previous average price target of $36.45.
<img src="https://www.benzinga.com/files/images/story/2025/1737054012_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
A clear picture of Zeta Global Holdings's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ryan MacDonald</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$43.00</td>
<td>$43.00</td>
</tr>
<tr>
<td>Elizabeth Porter</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$23.00</td>
<td>$26.00</td>
</tr>
<tr>
<td>Matthew Swanson</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$40.00</td>
<td>$43.00</td>
</tr>
<tr>
<td>Gabriela Borges</td>
<td>Goldman Sachs</td>
<td>Announces</td>
<td>Neutral</td>
<td>$30.00</td>
<td>-</td>
</tr>
<tr>
<td>Matthew Swanson</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$43.00</td>
<td>$43.00</td>
</tr>
<tr>
<td>Ryan MacDonald</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$43.00</td>
<td>$43.00</td>
</tr>
<tr>
<td>David Hynes</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$28.00</td>
<td>$24.00</td>
</tr>
<tr>
<td>Clark Wright</td>
<td>DA Davidson</td>
<td>Maintains</td>
<td>Buy</td>
<td>$42.00</td>
<td>$42.00</td>
</tr>
<tr>
<td>Elizabeth Porter</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$26.00</td>
<td>$41.00</td>
</tr>
<tr>
<td>Ryan MacDonald</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$43.00</td>
<td>$43.00</td>
</tr>
<tr>
<td>David Hynes</td>
<td>Canaccord Genuity</td>
<td>Lowers</td>
<td>Buy</td>
<td>$24.00</td>
<td>$42.00</td>
</tr>
<tr>
<td>Ryan Macwilliams</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$32.00</td>
<td>$28.00</td>
</tr>
<tr>
<td>Elizabeth Porter</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$41.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Clark Wright</td>
<td>DA Davidson</td>
<td>Raises</td>
<td>Buy</td>
<td>$42.00</td>
<td>$39.00</td>
</tr>
<tr>
<td>Jason Kreyer</td>
<td>Craig-Hallum</td>
<td>Raises</td>
<td>Buy</td>
<td>$45.00</td>
<td>$37.00</td>
</tr>
<tr>
<td>Terry Tillman</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$42.00</td>
<td>$35.00</td>
</tr>
<tr>
<td>David Hynes</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$42.00</td>
<td>$35.00</td>
</tr>
<tr>
<td>Matthew Swanson</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$43.00</td>
<td>$37.00</td>
</tr>
<tr>
<td>Brian Schwartz</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$42.00</td>
<td>$33.00</td>
</tr>
<tr>
<td>Ryan MacDonald</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$43.00</td>
<td>$36.00</td>
</tr>
<tr>
<td>Brian Schwartz</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$33.00</td>
<td>$29.00</td>
</tr>
<tr>
<td>Jackson Ader</td>
<td>Keybanc</td>
<td>Announces</td>
<td>Overweight</td>
<td>$40.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Zeta Global Holdings. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Zeta Global Holdings compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Zeta Global Holdings's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Zeta Global Holdings's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/ZETA/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Zeta Global Holdings analyst ratings.</a>
<h2>About Zeta Global Holdings</h2>
Zeta Global Holdings Corp is an omnichannel data-driven cloud platform that provides enterprises with consumer intelligence and marketing automation software. It serves enterprise customers across multiple industries, including financial services, insurance, telecommunications, automotive, travel and hospitality, and retail. Its Zeta Marketing Platform, or ZMP, is an omnichannel marketing platform with identity data at its core. The ZMP can analyze billions of structured and unstructured data points to predict consumer intent by leveraging sophisticated machine learning algorithms and the industry's opted-in data set for omnichannel marketing.
<h3>Unraveling the Financial Story of Zeta Global Holdings</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Revenue Growth: Zeta Global Holdings's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2024, the company achieved a revenue growth rate of approximately 41.97%. This indicates a substantial increase in the company's top-line earnings. When compared to others in the Information Technology sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Zeta Global Holdings's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -6.48% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Zeta Global Holdings's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of -5.02%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): Zeta Global Holdings's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of -2.39%, the company may face hurdles in achieving optimal financial performance.
Debt Management: Zeta Global Holdings's debt-to-equity ratio is below the industry average at 0.41, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>What Are Analyst Ratings?</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ZETA

What 22 Analyst Ratings Have To Say About Zeta Global Holdings

Citigroup analyst Steven Enders maintains OneStream (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OS#NASDAQ">OS</a>) with a Neutral and lowers the price target from $36 to $32.

Citigroup Maintains Neutral on OneStream, Lowers Price Target to $32

Nvidia Corp&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) demand for <a target="_blank" href="https://www.benzinga.com/topic/semiconductors" rel="noreferrer noopener">advanced packaging from</a> Taiwan Semiconductor Manufacturing Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSM#NYSE">TSM</a>) remains robust despite its evolving technology requirements, Reuters cites Nvidia chief Jensen Huang in response to its order cut plans.
Huang voiced plans to employ Chip-On-Wafer-On-Substrate-L&nbsp;(CoWoS-L) for its Blackwell transition and gradually ramp up capacity into the technology despite depending on CowoS-S for its Hopper artificial intelligence (AI) chip.
For context, Nvidia has relied mainly on CoWoS-S to combine its AI chips.
Nvidia&#8217;s Blackwell AI chip leverages Taiwan Semiconductor&#8217;s CoWoS advanced packaging technology.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/earnings/25/01/43022654/taiwan-semiconductor-q4-earnings-3nm-and-5nm-nodes-lead-topline-growth-expands-margins-issues-strong-q1-outlook" rel="noreferrer noopener">Taiwan Semiconductor Q4 Earnings: 3nm and 5nm Nodes Lead Topline Growth, Expands Margins, Issues Strong Q1 Outlook</a>
<figure class="wp-block-image size-full"><img loading="lazy" decoding="async" width="750" height="650" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/16122503/newplot-5.png" alt="" class="wp-image-737361" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/16122503/newplot-5.png 750w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/16122503/newplot-5-300x260.png 300w" sizes="(max-width: 750px) 100vw, 750px" /></figure>
Recently, TF International Securities analyst Ming-Chi Kuo and the Taiwan media flagged Nvidia&#8217;s shift to CoWoS-L, which is likely affecting the Taiwanese chipmaker&#8217;s CowoS-S revenue.
Due to capacity constraints, packaging has remained a bottleneck for the Blackwell chips, <a target="_blank" href="https://www.benzinga.com/news/24/05/39060364/nvidia-accelerates-ai-chip-production-with-new-packaging-tech-to-meet-soaring-demand" rel="noreferrer noopener">prompting Nvidia to</a> employ Fan-Out Panel Level Packaging (FOPLP) technology for its GB200 AI server chips.
Still, Huang said that the advanced packaging capacity was &#8220;probably four times&#8221; the amount available less than two years ago.
<a target="_blank" href="https://www.benzinga.com/markets/equities/24/11/41706702/nvidia-supplier-tsmc-to-double-advanced-chip-packaging-capacity-as-ai-demand-from-microsoft-amaz" rel="noreferrer noopener">Prior reports indicated</a> Taiwan Semiconductor will likely double its CoWoS production capacity in 2025, with Nvidia likely to occupy over 50% of the capacity.
Despite Taiwan Semiconductor&#8217;s efforts to ramp up production, the demand for advanced packaging continues to exceed supply, prompting it to double its CoWoS production capacity by 2025.
Price Actions: At last check on Thursday, NVDA stock was down 1.52% to $134.18. TSM is up 4.99%.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/25/01/42980720/microsoft-taps-meta-veteran-to-lead-new-coreai-division-plans-shift-from-openai-dependence" target="_blank" rel="noreferrer noopener">Microsoft Launches CoreAI Division: Ex-Meta Exec To Supercharge Copilot And AI Innovations</a></li>
</ul>
Photo via Shutterstock

Tech

Media

NVDA

Nvidia Continues Strong Demand for Taiwan Semiconductor's Advanced Packaging Despite Technology Shifts

Citigroup analyst Steven Enders maintains Dayforce (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DAY#NYSE">DAY</a>) with a Buy and lowers the price target from $90 to $83.

Citigroup Maintains Buy on Dayforce, Lowers Price Target to $83

U.S. stocks traded lower toward the end of trading, with the Nasdaq Composite falling over 150 points on Thursday.
The Dow traded down 0.27% to 43,106.65 while the NASDAQ fell 0.79% to 19,356.43. The S&amp;P 500 also fell, dropping, 0.28% to 5,933.22.
Check This Out: <a href="https://www.benzinga.com/news/earnings/25/01/43026927/how-to-earn-500-a-month-from-j-b-hunt-transport-stock-ahead-of-q4-earnings">How To Earn $500 A Month From J.B. Hunt Transport Stock Ahead Of Q4 Earnings</a>
Leading and Lagging Sectors Utilities shares surged by 2.3% on Thursday.
In trading on Thursday, consumer discretionary shares fell by 1.1%.
Top Headline
On Thursday, Morgan Stanley (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MS#NYSE">MS</a>) reported upbeat earnings for its fourth quarter.
The bank posted fourth-quarter adjusted EPS of $2.22, up from $0.85 a year ago and beating the consensus of $1.70. Net earnings more than doubled from $1.52 billion to $3.7 billion.
The U.S. bank reported fourth-quarter revenue of $16.22 billion, up 26% year over year, beating the consensus of $15.03 billion.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Biomerica, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMRA#NASDAQ">BMRA</a>) shares shot up 102% to $0.6820 after the company announced its Fortel Prostate Specific Antigen Screening Test received approval from the United Arab Emirates Ministry of Health and Prevention.</li>
<li>Shares of DouYu International Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DOYU#NASDAQ">DOYU</a>)got a boost, surging 26% to $15.53 as the company appointed Simin Ren as Co-CEO and declared a special cash dividend.</li>
<li>Symbotic Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SYM#NASDAQ">SYM</a>) shares were also up, gaining 19% to $31.88 after the company disclosed a deal to acquire Walmart Inc.'s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMT#NYSE">WMT</a>) Advanced Systems and Robotics business.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Leafly Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LFLY#NASDAQ">LFLY</a>) shares dropped 45% to $0.8001 after the company announced it received a Nasdaq desliting notice and will transition to the over-the-counter market.</li>
<li>Shares of Atara Biotherapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATRA#NASDAQ">ATRA</a>) were down 34% to $8.70 after the company issued regulatory and business update on EBVALLOTM (tabelecleucel).</li>
<li>Polestar Automotive Holding UK PLC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSNY#NASDAQ">PSNY</a>) was down, falling 11% to $1.09 after the company reported preliminary third-quarter revenue of $551 million, down 10% year over year, citing lower volume and competitive market conditions.</li>
</ul>
Commodities In commodity news, oil traded down 1.9% to $78.49 while gold traded up 1.4% at $2,755.10.
Silver traded up 1% to $31.860 on Thursday, while copper rose 1.1% to $4.4350.
Euro zone
European shares closed mostly higher today. The eurozone's STOXX 600 surged 0.98%, Germany's DAX 40 gained 0.39% and France's CAC 40 gained 2.14%. Spain's IBEX 35 Index fell 0.49%, while London's FTSE 100 gained 1.09%.
Asia Pacific Markets
Asian markets closed higher on Thursday, with Japan's Nikkei 225 gaining 0.33%, China's Shanghai Composite Index gaining 0.28%, Hong Kong's Hang Seng Index climbing 1.23% and India's BSE Sensex rising 0.42%.
Economics
<ul>
<li>U.S. retail sales rose 0.4% month-over-month in December versus a revised 0.8% increase in the previous month and down from market estimates of 0.6%.</li>
<li>U.S. initial jobless claims increased by 14,000 from the previous week to 217,000 in the week ending January 11, compared to market estimates of 210,000.</li>
<li>Import prices increased by 0.1% from the previous month in December, while export prices gained by 0.3% in December.</li>
<li>The Philadelphia Fed Manufacturing Index rose to 44.3 in January compared to a revised reading of -10.9 in the previous month.</li>
<li>The NAHB/Wells Fargo Housing Market Index rose to 47 in January compared to 46 in the prior two months.</li>
<li>U.S. business inventories increased by 0.1% month-over-month in November compared to a revised flat reading in the previous month.</li>
<li>U.S. natural-gas stocks fell 258 billion cubic feet during the week ending Jan. 1, the EIA said.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/25/01/43025282/wall-streets-most-accurate-analysts-views-on-3-energy-stocks-with-over-7-dividend-yields">Wall Street&#8217;s Most Accurate Analysts&#8217; Views On 3 Energy Stocks With Over 7% Dividend Yields</a></li>
</ul>

Earnings

Equities

Eurozone

Commodities

Intraday Update

Trading Ideas

ATRA

BMRA

DOYU

LFLY

PSNY

Nasdaq Down 150 Points; Morgan Stanley Earnings Top Estimates

Citigroup analyst Steven Enders maintains Asana (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ASAN#NYSE">ASAN</a>) with a Neutral and raises the price target from $16 to $20.

ASAN

Citigroup Maintains Neutral on Asana, Raises Price Target to $20

The Bank of New York Mellon Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BK#NYSE">BK</a>) shares are <a target="_blank" href="https://www.benzinga.com/premarket" rel="noreferrer noopener">trading slightly lower on Thursday.</a>
Yesterday, the company reported&nbsp;<a target="_blank" href="https://www.benzinga.com/25/01/42999464/bny-exceeds-q4-targets-with-strong-revenue-and-margins-showing-confidence-in-its-strategy" rel="noreferrer noopener">fourth-quarter 2024 results</a>. The finance behemoth reported fourth-quarter adjusted earnings per share of $1.72 (+33% YoY),&nbsp;<a target="_blank" href="https://www.benzinga.com/earnings" rel="noreferrer noopener">beating the street view of $1.56.</a>
Here are some analysts&#8217; take on the stock:
<ul>
<li>Goldman Sachs analyst Alexander Blostein reiterated the Buy rating on the stock, raising the <a href="https://www.benzinga.com/quote/BK/analyst-ratings" target="_blank" rel="noreferrer noopener">price forecast to $96 from $91.</a></li>
<li>Keefe, Bruyette &amp; Woods analyst David Konrad maintained the Outperform rating on the stock, with a price forecast of $96.</li>
<li>Truist Securities analyst David Smith maintained the Buy rating, with a price forecast of $91.</li>
</ul>
Goldman Sachs: The analyst sees the company&#8217;s 2025 and medium-term targets suggest a strong 10%+ EPS growth, not fully reflected in the stock&#8217;s 11X 2025 P/E.
Per the analyst, the management team is gaining credibility, which could lead to increased investor confidence and higher valuations.
Blostein writes that key factors supporting the Buy rating include better NII growth, which is 6% higher than consensus due to improved deposit levels, positive fee income growth driven by a differentiated business mix, and continued expense management with 1% &#8211; 2% growth expected in 2025.
The analyst sees potential for sustained positive operating leverage and appreciates the growing investor recognition of the fee growth potential. EPS estimates for 2025, 2026, and 2027 have been raised by the analyst to $7.09, $8.15, and $9.26, from $6.79, $7.81, and $8.79 respectively, reflecting higher growth compared to consensus.
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/25/01/43031980/big-banks-continue-to-beat-q4-earnings-financial-etf-takes-breather" rel="noreferrer noopener">Big Banks Continue To Beat Q4 Earnings As Financial ETF Takes A Breather</a>
Keefe, Bruyette &amp; Woods: The analyst raised 2025 and 2026 EPS estimates by $0.15 to $6.80 and $0.10 to $7.65, respectively, due to improved deposit behavior and higher NII expectations.
Per Konrad, while deposits are expected to moderate in 2025, the strong results in the second half of 2024 are projected to drive 5% NII growth in 2025.
Despite recent outperformance, the analyst sees a significant upside as the stock is trading in line with peers.
Truist Securities: The outlook for the year is neutral, with fees expected to rise YoY, the analyst writes.
Per Smith, a 5% increase in markets could add ~$70 million in annualized fees.
BNY plans to invest $0.5 billion, double its 2024 investment. The effective tax rate is expected to be 22% &#8211; 23%.
The analyst writes, by the first quarter of 2025, over half of the company&#8217;s workforce will operate on the platform model, with plans for 85% by year-end.
Price Action: BK shares are trading lower by 0.69% to $81.47 at last check Thursday.
Read now:
<ul>
<li><a href="https://www.benzinga.com/economics/macro-economic-events/25/01/43027744/retail-sales-slow-jobless-claims-rise-is-us-consumer-loosing-steam" target="_blank" rel="noreferrer noopener">Retail Sales Disappoint, Jobless Claims Rise: Is US Consumer Losing Steam?</a></li>
</ul>
Photo via Shutterstock.

Analyst Color

Reiteration

Movers

General

Bank Of New York Mellon's Differentiated Business Mix And NII Growth Signal Upside: Goldman Sachs

Maxim Group analyst Jason McCarthy maintains OS Therapies (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/OSTX#AMEX">OSTX</a>) with a Buy and raises the price target from $8 to $15.

OSTX

Maxim Group Maintains Buy on OS Therapies, Raises Price Target to $15

GLNCY

Rio Tinto, Glencore Are Said To Discuss Potential Combination

Kanavos Inc. has announced a strategic partnership with Graphwise, a global leader in semantic AI technologies, and HomeLab, a prominent biotech accelerator based at UC San Diego, to develop the Cannabis Knowledge Graph. 
Graphwise, known for its expertise in creating advanced knowledge graph solutions, brings a deep understanding of data organization and AI-powered insights, making it an ideal partner for this initiative. HomeLab, a key player in fostering biotech innovation, has supported more than 50 startups and helped raise more than $1.5 billion in funding, positioning it as a trusted hub for life sciences innovation. 
The Cannabis Knowledge Graph, aimed at providing patients and healthcare providers with accessible, evidence-based insights into cannabinoid therapies, was unveiled this week in San Francisco, coinciding with the J.P. Morgan Healthcare Conference taking place in the city. This announcement represents a significant step toward addressing the fragmented state of cannabis research and empowering more informed treatment decisions.
<h2 class="wp-block-heading">A New Approach To Cannabis Medicine</h2>
The Cannabis Knowledge Graph is still under development, but its goals are clear: to provide cannabis patients a unified source to discover scientific evidenced based therapeutics empowering personalized actionable decisions, consolidate clinical trials, preclinical research and real-world evidence into a unified resource. By leveraging Graphwise's Semantic AI technology, Kanavos aims to create a tool that provides actionable, personalized insights to patients and providers navigating cannabinoid-based medicine.
At its core, a knowledge graph is a data structure that organizes information by mapping relationships between entities. In the context of cannabis medicine, this means connecting diverse data sources—such as scientific evidence-based research with provenance, clinical trials, and patient outcomes—to reveal meaningful patterns and actionable insights. Unlike traditional databases, which simply store information, a Semantic AI knowledge graph enables AI systems to interpret and understand the meaning behind human language, concepts and data. This allows for a deeper understanding of how data points are interconnected, making it particularly valuable for complex fields like healthcare.
"This partnership with Graphwise marks a significant milestone for patients seeking to leverage the therapeutic potential of cannabinoids," said Dr. Deborah McGuinness, chief knowledge officer at Kanavos. "By combining our deep domain expertise with Graphwise's leading-edge technology, we are empowering individuals with the knowledge and insights they need to make informed healthcare decisions."
<h2 class="wp-block-heading">Addressing Critical Industry Challenges</h2>
The fragmented nature of cannabis research has long been a challenge for patients and providers. The Cannabis Knowledge Graph seeks to address this by organizing and contextualizing data, enabling users to compare therapeutic options and make more informed decisions. Unlike generative AI tools, the platform focuses on understanding relationships in data to deliver meaningful insights.
"By connecting disparate data sources – from Open LinkedLife Data to 80 million research publications, clinical trials to real-world evidence with provenance – we can unlock invaluable insights and empower patients with the information they need to make informed healthcare decisions," said Antanas Kiryakov, president of Graphwise.
<h2 class="wp-block-heading">The Road Ahead</h2>
Kanavos&#8217; partnerships include licenses for adult-use cannabis and DEA Schedule 1 drug manufacturing for research and development, positioning the company to explore novel therapeutic applications for cannabinoids as the Cannabis Knowledge Graph takes shape. This initiative is part of a broader trend of applying advanced semantic AI technologies to life sciences, healthcare and the wellness industries. The goal is to legitimize and expand the use of cannabinoids in therapeutic settings through rigorous data integration and actionable insights.
By building this platform, Kanavos is contributing to the broader adoption of data-driven solutions in healthcare. The company's collaborations with Graphwise and HomeLab aim to address challenges in cannabis research and facilitate advancements in cannabinoid-based medicine.
Cover image made with AI

Cannabis

Can AI Solve Cannabis Medicine's Data Problem? New Tech Initiative Aims To Streamline Research And Treatments

DouYu International Holdings (DOYU) has released an update. DouYu International Holdings reported a significant decline in revenue and profit for Q...

DouYu Q3 2024: Revenue Decline Amid Strategic Shifts

Check out this morning's top movers from around Wall Street, compiled by The Fly. HIGHER – Comcast (CMCSA) up 2% after announcing its intent to cre...

Morning Movers: Target tumbles following earnings release

Douyu International Holdings ( ($DOYU) ) has released its Q3 earnings. Here is a breakdown of the information Douyu International Holdings presente...

DouYu International Highlights Q3 2024 Financial Performance

DouYu International Q3: Exodus Of Subscribers Continues, But There Is Hope

DouYu International Holdings Limited (DOYU) Q3 2024 Earnings Call Transcript

DouYu International declares $9.94 dividend

DouYu appoints co-CEO

DouYu (DOYU) announced that the company's board of directors appointed Simin Ren as the company's co-CEO effective immediately, following the trans...

DouYu appoints Simin Ren as co-CEO, $9.94 per share special cash dividend

The latest announcement is out from DouYu International Holdings ( ($DOYU) ). On January 16, 2025, DouYu International Holdings Limited announced t...

DouYu Announces Co-CEO Appointment and Special Dividend

Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. 1. STOCK NEWS: UnitedHealth (UNH) reported upbeat Q4 ...

UnitedHealth, BofA report Q4 earnings beats: Morning Buzz

AAPL

BORR

BPAQF

CMCSA

EOSE

EQNR

GOOG

GOOGL

HUYA

KSHTY

KUASF

MASI

NFLX

PSNYW

RZLV

Entertainment

Social Media

Press Releases

DouYu International Holdings Limited to Report First Quarter 2024 Financial Results on June 5, 2024

DouYu International Holdings Limited Reports First Quarter 2024 Unaudited Financial Results

Dividends

DouYu International Holdings Limited Announces Special Cash Dividend

DouYu International Holdings Limited Announces Ex-dividend Date

LightInTheBox Announces Appointment of Director and Chairman of the Board

DouYu International Holdings Limited to Report Second Quarter 2024 Financial Results on September 12, 2024

DouYu International Holdings Limited Reports Second Quarter 2024 Unaudited Financial Results

DouYu International Holdings Limited to Report Third Quarter 2024 Financial Results on November 20, 2024

DouYu International Holdings Limited Reports Third Quarter 2024 Unaudited Financial Results

DouYu International Holdings Limited Announces the Appointment of Co-CEO and Special Cash Dividend

LITB

Blue Hat Interactive Entertainment Technology - Ordinary Shares

Blue Hat Interactive

DoubleDown Interactive Co., Ltd. - American Depository Shares

DoubleDown Interactive

Electronic Arts

GDEV

Golden Matrix Group

GRAVITY Co., Ltd. - American depositary shares, each representing one common share.

GRAVITY Co

Gaxos.AI

HUYA Inc. American depositary shares, each representing one Class A ordinary share

iHuman Inc. American depositary shares, each representing five Class A ordinary shares

iHuman

Motorsport Games Inc. - Class A Common Stock

Motorsport Games

PLAYSTUDIOS

NetEase, Inc. - American Depositary Shares, each representing 5 ordinary shares

NetEase

Playtika Holding

Roblox

Sea Limited American Depositary Shares, each representing one Class A Ordinary Share

Skillz

Snail

Sohu.com Limited - American Depositary Shares

Sohu.com

TruGolf Holdings, Inc. - Class A Common Stock

TruGolf Holdings

Take-Two Interactive Software, Inc. - Common Stock

Comments

DouYu Intl Hldgs

空売り

DouYu Intl Hldgs (NASDAQ:DOYU) 株価情報, 空売り情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル